207 related articles for article (PubMed ID: 6998710)
41. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition.
Kiowski W; Linder L; Kleinbloesem C; van Brummelen P; Bühler FR
Circulation; 1992 Jan; 85(1):1-8. PubMed ID: 1728438
[TBL] [Abstract][Full Text] [Related]
42. Role of bradykinin potentiation in the antihypertensive effect of captopril in conscious rabbits with two-kidney, one-clip hypertension.
Takata M; Sugimoto T; Matsumoto M; Iida H; Mizumura Y
J Cardiovasc Pharmacol; 1981; 3(6):1260-8. PubMed ID: 6173526
[TBL] [Abstract][Full Text] [Related]
43. Regulation of prostacyclin generation by angiotensin converting enzyme related substances in cultured human vascular endothelial cells.
Nakagawa M; Sawada S; Toyoda T; Takamatsu H; Tsuji H; Ijichi H
Clin Exp Hypertens A; 1987; 9(2-3):405-8. PubMed ID: 3038403
[TBL] [Abstract][Full Text] [Related]
44. Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man.
Swartz SL; Williams GH; Hollenberg NK; Levine L; Dluhy RG; Moore TJ
J Clin Invest; 1980 Jun; 65(6):1257-64. PubMed ID: 6997332
[TBL] [Abstract][Full Text] [Related]
45. Single-dose captopril administration in DOCA/salt rats: reduction of hypotensive effect by indomethacin.
Miyamori I; Brown MJ; Dollery CT
Clin Exp Hypertens (1978); 1980; 2(6):935-45. PubMed ID: 7004806
[TBL] [Abstract][Full Text] [Related]
46. Converting enzyme inhibition during chronic angiotensin II infusion in rats. Evidence against a nonangiotensin mechanism.
Textor SC; Brunner HR; Gavras H
Hypertension; 1981; 3(2):269-76. PubMed ID: 6260647
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of angiotesin-converting enzyme by quercetin alters the vascular response to brandykinin and angiotensin I.
Häckl LP; Cuttle G; Dovichi SS; Lima-Landman MT; Nicolau M
Pharmacology; 2002 Aug; 65(4):182-6. PubMed ID: 12174832
[TBL] [Abstract][Full Text] [Related]
48. Nitric oxide modulates captopril-mediated angiotensin-converting enzyme inhibition in porcine iliac arteries.
Persson K; Andersson RG
Eur J Pharmacol; 1999 Nov; 385(1):21-7. PubMed ID: 10594341
[TBL] [Abstract][Full Text] [Related]
49. Angiotensin II type 2 receptor-mediated and nitric oxide-dependent renal vasodilator response to compound 21 unmasked by angiotensin-converting enzyme inhibition in spontaneously hypertensive rats in vivo.
Brouwers S; Smolders I; Massie A; Dupont AG
Hypertension; 2013 Nov; 62(5):920-6. PubMed ID: 24041944
[TBL] [Abstract][Full Text] [Related]
50. Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition.
Silberbauer K; Stanek B; Templ H
Br J Clin Pharmacol; 1982; 14 Suppl 2(Suppl 2):87S-93S. PubMed ID: 6753910
[TBL] [Abstract][Full Text] [Related]
51. Angiotensin-converting enzyme inhibition and prostaglandins.
Swartz SL; Williams GH
Am J Cardiol; 1982 Apr; 49(6):1405-9. PubMed ID: 6280473
[TBL] [Abstract][Full Text] [Related]
52. Angiotensin II stimulation of renal prostaglandin synthesis elevates circulating prostacyclin in the dog.
Shebuski RJ; Aiken JW
J Cardiovasc Pharmacol; 1980; 2(5):667-77. PubMed ID: 6157958
[TBL] [Abstract][Full Text] [Related]
53. The increase in coronary flow induced by converting enzyme inhibitors is prostacyclin independent.
Tio RA; van Wijngaarden J; Scholtens E; van Gilst WH; de Langen CD; Wesseling H
Prog Clin Biol Res; 1989; 301():435-9. PubMed ID: 2552464
[No Abstract] [Full Text] [Related]
54. Renal, adrenal and vascular changes during inhibition of converting enzyme with captopril.
Clappison BH; Millar JA; Casley DJ; Anderson WP; Johnston CI
Clin Exp Pharmacol Physiol; 1980; 7(5):493-8. PubMed ID: 6256104
[TBL] [Abstract][Full Text] [Related]
55. Captopril increases skin microvascular blood flow secondary to bradykinin, nitric oxide, and prostaglandins.
Warren JB; Loi RK
FASEB J; 1995 Mar; 9(5):411-8. PubMed ID: 7896012
[TBL] [Abstract][Full Text] [Related]
56. Differing effects of two angiotensin converting enzyme inhibitors, captopril and CI-906, on diuresis and the urinary excretion of kallikrein and prostaglandins in spontaneously hypertensive rats.
Säynävälammi P; Pörsti I; Nurmi AK; Seppälä E; Laitinen LA; Manninen V; Ylitalo P; Vapaatalo H
Scand J Urol Nephrol Suppl; 1984; 79():23-7. PubMed ID: 6089314
[TBL] [Abstract][Full Text] [Related]
57. Long-term effects of captopril (SQ14 225) on blood-pressure and hormone levels in essential hypertension.
Johnston CI; Millar JA; McGrath BP; Matthews PG
Lancet; 1979 Sep; 2(8141):493-6. PubMed ID: 90216
[TBL] [Abstract][Full Text] [Related]
58. Chronotropic effects of angiotensin I, angiotensin II, bradykinin and vasopressin in guinea pig atria.
Nakashima A; Angus JA; Johnston CI
Eur J Pharmacol; 1982 Jul; 81(3):479-85. PubMed ID: 6749532
[TBL] [Abstract][Full Text] [Related]
59. Role of endogenous bradykinins in the acute depressor effect of angiotensin converting enzyme inhibitor captopril--assessed by a competitive antagonist of bradykinin.
Seino M; Abe K; Nushiro N; Omata K; Yoshinaga K
Clin Exp Hypertens A; 1989; 11(1):35-43. PubMed ID: 2653669
[TBL] [Abstract][Full Text] [Related]
60. Bradykinin B2 receptor-mediated chronotropic effect of bradykinin in isolated guinea pig atria.
Tesfamariam B; Allen GT; Powell JR
Eur J Pharmacol; 1995 Jul; 281(1):17-20. PubMed ID: 8566111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
